News

Patients with rheumatoid arthritis who have high disease-related brain activity due to painful joint compression are more ...
Interleukin-2 (IL-2) inhibitors are immunosuppressive agents that block the activity of IL-2, a cytokine involved in the activation and proliferation ...
Discover a study uncovering how JAK inhibitors protect against autoimmune diabetes triggered by cancer immunotherapy.
Turn Therapeutics began a clinical trial for its atopic dermatitis candidate, marking the first clinical trial of a topical ...
Discover a study comparing the effectiveness, safety, and tolerability of 39 treatments for moderate to severe hidradenitis suppurativa.
Market OverviewThe global Cancer Immunotherapy Market is valued at USD 121.4 Billion in 2024 and is projected to reach a ...
Emerging evidence indicates JAK inhibitors could be a valuable alternative for managing checkpoint inhibitor–induced immune toxicities, especially in difficult-to-treat cases.
Immune checkpoint inhibitors have changed the future of cancer care. These powerful treatments use the body’s own immune ...
Inhibition of epigenetic modifiers has been shown to elicit an immunostimulatory response via upregulation of cytokine production and antigen presentation as well as by inhibition of Tregs. 222 In an ...
Vyne Therapeutics has given up hopes of resuming a plaque psoriasis trial for its BET inhibitor placed on hold by the FDA, ...
Researchers are working to launch a first-in-human clinical trial to test the approach in patients with cancer who develop diabetes after immunotherapy.